Cognition Therapeutics, Inc. announced that its Phase 2 START Study, aimed at evaluating zervimesine (CT1812) for treating early Alzheimer’s disease, has surpassed 50% enrollment, with support from an ...

MAIA Biotechnology, Inc. ((MAIA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...